Management of diabetes and diabetes policies in Turkey by unknown
REVIEW Open Access




Background: Diabetes and its complications are among the present and future challenges of the Turkish health
care system. The objective of this paper is to discuss the current situation of diabetes and its management in
Turkey with special emphasis on the changing policy environment.
Methods: A literature review in databases such as PUBMED was performed from 2000 to 2011. This synthesis was
complemented by grey literature, personal communication and contact with national and provincial health
authorities and experts in diabetes from Turkey.
Results: The literature review and expert consultations indicated a growing policy emphasis on diabetes. Both the
public and private sectors, non-governmental organizations have initiated policy papers to shape the outlook of
diabetes care in the future. This is in line with the current dynamics of the healthcare system.
Conclusions: Diabetes care will be high on the agenda in future. Evidence based policy-making is the key to
implement the policies adopted so far and a supportive environment is needed.
Keywords: Diabetes care, Turkey, Turkish healthcare policy
Introduction and objectives
Turkey has been undergoing a radical reform process
since the beginning of the Health Transformation Pro-
gram (HTP) in 2003 [1]. The major focus areas of this
transformation have been on the purchaser provider split,
reorganizing the primary and secondary level of care and
the introduction of a general health insurance scheme.
Before 2003, Turkey had a very fragmented health care
system with large inequalities among different segments
of the population. Accessibility, equality, quality and effi-
ciency problems were the main concerns of the Turkish
healthcare system before 2003. The government addressed
the inequality problem by merging all existing public
financing schemes under the Social Security Institution
with gradual equalization of health benefits packages of
these schemes. The monopsonic power of the SSI as the
main purchaser of health care services both from the pub-
lic and private sector has also shifted the balance of health
policy-making power from the Ministry of Health (MoH)
to the organization. The reimbursement rules applied by
the organization shape not only the financing but also
provision of health care services as well.
Major policy changes were introduced in the provision
of health care services as well. As in the case of financing,
health care services were also very fragmented and access
was restricted for the majority of the population before
2003. First, health care facilities of other organizations
with the exception of the university and the Ministry of
Defense facilities were transferred to the MoH. Second, a
family practitioner scheme was introduced that changed
the organization of the primary level of care. Although
there is not a compulsory referral system yet, family prac-
titioners play an important role in improving access to the
health care system. A number of other changes supporting
the transformation of the system were also made such as
introduction of a performance based payment system,
changes in the reimbursement and pricing policies and
others. A detailed analysis of the current health care
system can be found in Tatar et al. [2].
Although a comprehensive impact assessment of these
reforms has not been made yet, improvements in se-
lected indicators confirm the analysis made here. The
main health indicators used to assess the health status
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level of a country have improved considerably after
2000. Although some part of this improvement is attrib-
utable to the advances in the socioeconomic indicators
as well, the improvements especially in accessibility
figures show that the HTP had a positive influence as
well. For instance, the infant mortality rate has de-
creased from 31.4 in 2002 to 7.7 in 2011 [3]. Life expect-
ancy has also increased from 70 in 2000 to 75 in 2011
[3]. In line with these improvements, the maternal mor-
tality rate has also declined in the past years and
according to the World Health Organization, Turkey is
among 14 countries which achieved more than a 5.5%
yearly decline in maternal mortality [4]. As far as the
main causes of death are concerned, Turkey has a list of
diseases similar to those from developed countries. The
Burden of Disease (BoD) study concluded in 2003 before
the implementation of HTP and showed that ischemic
heart disease and cerebrovascular diseases were among
the highest causes of deaths with 21.7% and 15% shares
in total deaths respectively. Diabetes Mellitus was ranked
8th on the list with a 2.2% share in total deaths [5]. A
more recent study conducted by the Turkish Statistics
Institute listed the top five causes of death as circulatory
system 39,9%, malignant neoplasms 20,7%, diseases of
the respiratory system 8,9%, Endocrine, nutritional and
metabolic diseases 6,4% and external causes of injury
and poisoning 4% [6].
The changing environment in the Turkish healthcare
system has also changed the approach to certain diseases
including diabetes. The objective of this paper is to dis-
cuss diabetes and its management in Turkey with special
emphasis on the changing policy environment and its
impact on health promotion policies in general and dia-
betes in particular.
Methodology
A literature review in PUBMED was performed from
2000 to 2011. This synthesis was complemented with
grey literature, personal communication and contact
with national and provincial health authorities and
experts in diabetes from Turkey. The literature review
was carried out with key words ‘diabetes-cost-Turkey’
and ‘diabetes-policy-Turkey’. Total 37 studies for the
former and 15 studies for the latter search was found.
None of the studies were directly related to the topic
searched and diabetes was in general taken in the sub-
group analysis of the study population. Experts in the
MoH and SSI were also consulted to explore the unpub-
lished data and policies. National policy documents and
all related documents from public and private stake-
holders including non-governmental organizations were
also the main sources of information.
The literature review revealed that both national and
international publications focused on the risk factors of
diabetes in certain sub-populations, treatment methods
of diabetes with special emphasis on complications,
prevalence of disease in small geographical areas and
few studies on quality of life measurements of diabetes
patients. The majority of these studies covered a small
sub-population or geographical area, making it impos-
sible to infer national figures.
Results
Turkey does not have an official diabetes registry and inter-
national and national surveys are the only data sources for
the burden of diabetes. Currently, a database study named
Health-Net is being developed under the second phase of
HTP. The Hospital Information System and Family Practi-
tioner Information System collect data on diagnosis date,
patient’s height, weight, waist measurement, exercise sta-
tus, compliance to diet, blood pressure, thyroid examin-
ation and co-morbidity. However, the lack of a referral
system is a barrier to having aggregate data on all health
indicators (including diabetes) as patients can visit any
facility any time without a referral from a lower level.
Prevalence
According to the 2011 Diabetes Atlas of the Inter-
national Diabetes Association (IDF), the adult popula-
tion between the ages of 20–79 was 47.322.400 in 2011
and diabetes cases among this population totalled
3.502.270. Diabetes is more prevalent among females
representing 58.1% of total diabetes cases. According to
the estimates of the IDF, 1.256.440 people have undiag-
nosed diabetes. This figure addresses a considerable
unmet need in diagnosis and treatment of diabetes in
the country. Estimated prevalence of diabetes was
reported as 7.4% and impaired glucose tolerance was
estimated at 6.7%. The number of diabetes related
deaths was estimated at 31.931 in the same report [7].
Four national surveys provide evidence about the bur-
den of diabetes in Turkey: The National Burden of Disease
and Cost Effectiveness Study [5]; The Turkish Diabetes
Epidemiology Study I [8] and II [9] (TURDEP I, TURDEP
II) and TEKHARF (The Turkish Adult Risk Factor Survey)
[10]. As stated earlier, in the burden of disease study
(BoD), diabetes was ranked 8th on the list of causes of
death with 2.2% share among total deaths in the country.
Diabetes constituted 1.9% of the total Disability Adjusted
Years (DALYs) and the figures were 1.64% for total Years
of Life Lost and 2.17% for total Years Lost with Disability.
The BoD study found the annual incidence of diabetes as
3.820 per 100,000 population (3.820 for males and 3.210
for females). The study concluded that the prevalence of
the disease was 6% [5].
TURDEP I and TURDEP II provide the most detailed
analysis of the epidemiology of diabetes in Turkey and
also allow comparison of figures between 1997–2010.
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TURDEP I was conducted between September 1997 to
March 1997 in 540 health centres across the nation.
29,050 eligible people from these centres were invited to
the survey and 24,788 completed the study. In order to
represent the age and gender structure at the regional
level, people aged 20 and over and living in defined set-
tlements were invited to the study
Blood tests and other measurements were taken to-
gether with a questionnaire to assess socioeconomic
characteristics [8]. TURDEP II [9] was conducted from
January to June 2010 in the same 540 centres with the
same methodology to allow for comparison of results.
26,499 people were invited to take part in the study from
these centres and 92% of the invitees participated in the
research. Table 1 below shows the results of the two
surveys.
TURDEP II study also revealed that measurements
reflecting the risk factors have increased from the first
study conducted 13 years earlier. For instance, weight
for females increased 8 kg since the first study and this
figure was 6 kg for males. Similar increases were also
observed in waist and hip measurements as well (waist
measures increased 6 cm for males, 7 cm for females;
hip measures increased 2 cm for males and 7 cm for
females). According to the study, diagnosis age of dia-
betes was five years earlier than the TURDEP I Study.
The study concluded that diabetes incidence has in-
creased 90% and obesity has increased 44% between the
two studies.
The last national survey providing data on diabetes was
the TEKHARF This study was aimed at assessing the car-
diovascular health of the population and included diabetes
as a risk factor. In the study, 3401 people were screened in
terms of diabetes between 1997/98 and 2004/2005. The
study concluded that the incidence of diabetes for those
35 and over reached 360,000 (1.22%) in 2008 [10].
Costs
Cost of disease studies are not very common in Turkey
and diabetes is not an exception. There are three sources
of information with methodological limitations. The first
one was undertaken in 1998 with the aim of estimating
the direct medical costs of diabetes in an adult popula-
tion. The study covered 959 patients enrolled in the
study for two months from 13 centres at the tertiary
level. Those included in the study had high systemic
complication rates and poor glycemic control. The study
concluded that the annual direct cost of diabetes treat-
ment per patient was USD$ 1,100-2,100 and half of this
cost was due to the treatment cost of the disease. The
cost for patients with complications of diabetes was
three times higher compared to the patients without
complications. The direct costs increased 6.5 fold in case
of hospitalization. As the study was undertaken in
tertiary facilities, the complication rates may not repre-
sent the complication rate in the Turkish population. In
order to take this into account, the researchers used a
range of 0-70% complication rate in their model and
estimated the overall annual direct cost of diabetes in
Turkey as USD$ 1–2.5 billion. They also concluded that a
10% increase in the complication rate added a cost of
USD$ 180–190 million to the overall cost of diabetes [11].
The second study regarding cost of diabetes screening
and treatment is the Burden of Disease and Cost Effect-
iveness Study [5]. In the study, the incidence of diabetes
was estimated as 38.20 per thousand (prevalence of
5.6%). Based on this assumption along with assumptions
regarding the effectiveness of the interventions, it was
concluded that population based screening and treat-
ment may prevent 828,835 cases per year in the long
run. The study’s estimates for diabetes treatment are
presented in Table 2.
The monitoring and treatment of diabetes had the
highest cost effectiveness ratio when compared with
other public health interventions. The high cost-
effectiveness ratio was attributed to the chronic charac-
ter of the disease with high prevalence and relatively
high cost of medical management of the disease. Al-
though the cost of intervention is high, the cost effect-
iveness ratio was found as USD$ 1,097 per DALY, less
than the GDP per capita of the time.
Costs of complications
The third study for the cost of diabetes treatment was
carried out from January 1- December 31 2009 to deter-
mine the direct costs of cardiovascular, ophthalmo-
logical, neurological and nephrological complications in
patients with diabetes. The study covered the real data
of 7,095 patients in that period and restricted results
were shared in a national diabetes congress. As there is
not any information on the methodology of the survey
Table 1 Results of TURDEP I and II
TURDEP I TURDEP II
1997 2010
Study population ≥ 20 year? 24 788 26 499




BMA≥30 kg/m2 22% 35.9%
High blood pressure prevalence 29% 31.3%
National prevalence 7.2% 13.7%
Impaired glucose tolerance 6.7% 6.3%
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currently, it is not possible to comment on the quality of
the conclusions reached. The study concluded that the
share of cardiovascular complications in the total cost of
diabetes was 32.6%. The figure was 25% for nephro-
logical complications, 6.4% for eye complications and 6%
for neurological complications. The study also concluded
that the pharmaceutical expenditures for diabetes treat-
ment constituted only 10.9% of the annual direct cost of
the disease to the SSI. Diabetes expenditures are not
seen as a separate item in the health care budget as dis-
ease specific budgeting is not done in Turkey. Therefore
the total amount of resources allocated to diabetes can-
not be estimated very easily.
In terms of comparison with other high incidence and
high mortality illnesses, diabetes patients are treated
equally in terms of diagnosis and treatment opportun-
ities. Diabetes patients are exempt from co-payments for
drugs if they are prescribed following the rules listed
below. There are also co-payments for visits to the
health care facilities. These co-payments increase from
primary to secondary and tertiary care and are highest in
case of private facilities. There are no exemptions from
these co-payments.
In terms of availability of medicines, there isn’t a
threat to the patients’ health, in other words, the re-
quired medicines at all stages of the treatment of the
disease are available in Turkey. However, as part of the
cost containment measures for all pharmaceuticals, in
the last two years the marketing and reimbursement
procedures for new molecules have slowed down.
Turkey uses both external and internal reference pricing
and public discounts for reimbursement of drugs. After
getting a marketing approval from the MoH, the lowest
price in France Greece, Italy, Spain and Portugal deter-
mines the price of the original drug is priced with. Once
a generic enters the market, the generic is priced at 60%
of the reference price and the price of the original also
decreases automatically to that level as well. The num-
ber of generics in the market does not change these
rates. After getting a market price for an original medi-
cine, the firm applies to the SSI for reimbursement with
a dossier covering effectiveness and safety date and
pharmacoeconomic analysis for the product. All original
drugs have to give 41% discount from the market price
in order to get a reimbursement approval.
The reimbursement agency can put restrictions on the
use of the medicine by enforcing rules. Turkey also has
an internal reference pricing system where all medicines
are clustered in drug equivalent groups and the SSI re-
imburses the cheapest price plus 10% in each group. If
the prescribed drug is over this band price, then the
patient has to pay the difference or the pharmacist sub-
stitutes the prescribed medicine with another one within
the band limits. The pricing and reimbursement envir-
onment has started to negatively impact the healthcare
environment as multinational companies have started to
re-evaluate their marketing strategies.
Discussion
The research outlined above reveals that the prevalence
of diabetes has doubled and the burden of the disease
on the Turkish healthcare system has increased. Multiple
factors may have played a role in the upsurge of the dis-
ease. First, the accessibility to the health care system has
improved considerably in the last decade and the prob-
ability of being diagnosed with the disease has also in-
creased. Second, as a part of the transformation
program, primary care services have also improved con-
siderably and after the introduction of the family practi-
tioner scheme diagnosis of diabetes at later stages may
have also improved. Third, life-style related risks are in-
creasing in Turkey as the increases in obesity rates etc.
shows.
The International Diabetes Association has made some
estimates about the health care expenditures for the
treatment of diabetes as well. For the year 2010, the
mean diabetes related expenditure per person with dia-
betes was calculated at USD$ 933. The number of
Table 2 Cost of diabetes treatment in Turkey (Results of the Burden of Disease Study)
Health centre based non-insulin
dependent diabetes treatment
(100% cases treated in health centres)
Hospital based treatment for
insulin dependent diabetes
(100% cases treated in hospitals)
Hospital based treatment for
non-insulin dependent diabetes
(100% cases treated in hospitals)
Cases to be treated 3 405 113 378 346 3 405 113
Incidence cases 2 331 099 259 011 2 331 099
No of deaths 8 594 955 8 594
DALYs saved 2 258 798 470 474 4 234 269
Cost/Case (USD$) 176.22 1 580.70 448.62
Cost/Case (USD$ PPP) 460.98 4 135.12 1 173.59
Total cost (USD$) 480 039 240.45 478 441 207.31 1 222 081 512.03
Cost per DALY (USD$) 222.36 1 016.93 288.62
[5].
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people with diabetes between 20–79 was estimated as
3,502,270 for the same year [11]. According to these
estimates, the figure for total diabetes expenditure for
2010 was more than USD$ 3 billion.
There is a growing need to study the cost of diabetes
and its share in total health care expenditures in Turkey.
This issue was tackled in the National Action Plan for
diabetes as well. One of the targets of the Plan was to
undertake regular cost of disease studies to support
effective and efficient management of the disease. The
following actions were listed to achieve the target [12]:
 Cost packages in line with the MoH diabetes care
standards would be prepared;
 Actions would be taken to enforce the MoH
diabetes standards for reimbursement decisions; and
 Actions would be taken to reimburse all activities
related to diabetes including education for diet,
physical activity and exercise.
Similar recommendations were also made in the Dia-
betes 2020 project as well. Cost of disease studies and
health technology assessments were proposed with spe-
cial emphasis on the societal perspective. These recent
initiatives support the claims that there will be more em-
phasis on the cost of diabetes in the Turkish health care
system.
The introduction of health promotion policies within
the overall context of health care policies gained pace
after 2008. As life style related chronic diseases started
to occupy the agenda, policies related to obesity, dia-
betes, and high blood pressure were accepted as priority
areas to focus on.
The MoH declared its first National Diabetes Program
in 1994 in line with the strategies declared in ‘St.
Vincent Declaration’. After the declaration of the pro-
gram, diabetes polyclinics and centres were established
in 15 provinces. The program was revised as ‘National
Diabetes, Obesity and Hypertension Program’ in 1996.
This program can be regarded as a pioneer of the
following policy initiatives. As similar initiatives in the
1990s the program did not meet the pre-determined
objectives.
In 2009 the initiation of the project ‘Diabetes 2020’
attracted the attention of different stakeholders to the
disease once again. The project supported by the MoH,
the World Health Organization and the IDF, was also a
very good example of inter-sectoral action in health care in
Turkey. Apart from the MoH and international partners, a
wide range of stakeholders from the non-governmental
organizations including patients, academicians and pro-
viders were involved in the project. In 2009, a comprehen-
sive report on the issues discussed in the diabetes
profile workshop was published [13]. The report
analyzed the current situation in diabetes from a
broad perspective and covered topics from the prevention
of diabetes and diabetes-related complications to the
coordination, organization and planning of diabetes care,
the financial and economic aspects of diabetes, and the
need for an information system for diabetes and a national
registry. The results of the second workshop that focused
on the solutions to the current problems were published
in 2010 [14].
The MoH, in line with its increasing emphasis on life
style policies and chronic diseases, launched the Turkish
Diabetes Prevention and Control Program in 2009. This
program also involved a large number of participants
from governmental organizations, non-governmental or-
ganizations, academicians, patient groups and health
care providers. In 2011, The Action Plan for 2011–2014
was published [12]. The objectives of the program were
set out as follows:
 Increasing awareness for diabetes and risk factors;
 Promoting public adoption of healthy life styles;
 Controlling diabetes through early diagnosis;
 Improving treatment and monitoring of diabetes in
line with current standards; and
 Decreasing diabetes-related complications.
In the Action Plan, targets for 2014 were determined,
followed by actions to be taken to achieve these targets.
The preparation of a national diagnosis and treatment
guideline for diabetes and its complications was stated
as the most critical step. According to the Plan, the
MoH Diabetes Standards determining the treatment
algorithm for the disease will be developed as the first
initiative of the program. This disease specific guideline
by the MoH will be its first example in the Turkish
health care system and will be the basis for reimburse-
ment of prevention, treatment and monitoring of the
disease. Indicator based targets are also determined in
the Action Plan. Some of these are as follows:
 The incidence, prevalence and impaired glucose
tolerance will be reduced by 5% by 2020.
 At least 10% of the general population will be
educated on diabetes in the first 5 years.
 The percentage of patients not aware of the disease
will be decreased by 10% in 5 years.
 Periodical cost analysis reports of the disease will
start to be published at the end of second year.
The MoH’s increasing emphasis on chronic diseases
and its special emphasis on diabetes are also reflected in
the recent changes in the organization of the Ministry.
As part of the HTP, the MoH was reorganized in
November 3, 2011. All the departments of the MoH
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were abolished and new ones were established to meet
the needs of the new health care system and changing
trends in the healthcare environment. Within this new
structuring, a new Directorate for Health Promotion was
established reflecting the importance attributed to
healthy life styles and health promotion in the future
health policies.
Although these policy initiatives indicate a clear deter-
mination to prioritize diabetes management in the
health care system, there are still caveats in implementa-
tion. It is not possible to state that the paradigm shift
occurring at the policy level is also happening at the pro-
vider level as well. The health care providers are still
very treatment oriented and this is fueled further by the
current performance based payment system. Family
practitioners are the main providers for implementation
of these policies but lack of a referral system may hinder
the attempts to use this professional force in the imple-
mentation of prevention-oriented policies. The introduc-
tion of additional incentives to the payment mechanism
of family practitioners and rewarding their extra efforts
may be useful in future.
As stated earlier, the SSI is the main reimbursement
agency in Turkey and rules of reimbursement are deter-
mined through the Health Implementation Guide (HIG)
published by the organization. In the latest available
HIG, the rules for diabetes are presented in Table 3.
Priorities for the future
The current emphasis on diabetes and its risk factors
marks the beginning of a new era in the Turkish health
care policy environment. In the past, the treatment-
oriented nature of the health care system had been criti-
cized fiercely for not taking into account preventive
services at the expense of curative services. The new
organization of the MoH can also positively influence
the implementation of new policies. However, only mak-
ing policies or developing action plans is not enough to
guarantee their implementation. There are a number of
priorities for the future regarding the management of
diabetes and its complications.
First, both making and implementing diabetes related
policies require an evidence-based approach. This indi-
cates the need for a better health information system.
Available epidemiologic and other data are not sufficient
to diagnose the real extent of the problem. The develop-
ment of a diabetes registry could be the first step for the
provision of necessary evidence. The government, acade-
micians, non-governmental organizations, patients and
health care providers should participate in the prepar-
ation of the information system as key stakeholders that
will use the end products of this system.
Second, the cost of diabetes and diabetes related com-
plications should be studied from the SSI and societal
perspective. The methodology of these studies should be
shared with the scientific community. The study should
be designed to represent the whole country.
Third, national diagnosis and treatment guidelines
should be developed with a wide participation from dif-
ferent professional areas. These guidelines must be
endorsed by the SSI and should form the basis for reim-
bursement decisions by the social security system.
Guidelines will also help to provide balanced diagnosis,
treatment and monitoring options to the citizens as well.
Table 3 Rules of reimbursement for diabetes treatment
Treatment Who can prescribe? Patient restrictions Other restrictions
Metformin, Sulfonylurea, human insulin All physicians - -
Repaglinide, nateglinide combined





Analog insulin, pioglitazone, oral
combinations of pioglitazone or







vildagliptine) and combination of DPP-4
antagonists by other oral anti-diabetics
Endocrinologists and
internists at tertiary level*
Only to patients without glycemic control after the use
of maximum tolerable dose treatment by metformin
and sulfonylurea
Exanatide Endocrinologists • Patients without glycemic control with the use of
metformin and sulfonylurea at maximum tolerable
doses and with a body mass index over 35 kg/m2





• Patients without history of pancreatitis
Blood glucose meters and strips • Endocrinologists, internists,
or specialized family
practitioners. *
* These can be prescribed by all physicians after a medical report issued by one of these specialists.
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Last but by no means the least, increasing awareness
of the public should be a priority in order to diagnose
and treat the disease at earlier stages. According to the
TURDEP II study, 45% of the participants were not
aware they had the disease. Given the fact that acces-
sibility is better than the past, this figure shows
other contributors have an impact on these figures.
The family practitioners are of special importance in
increasing this awareness. The family practitioners
should be trained to detect and follow the risk factors
of diabetes among their patients. Special training ses-
sions can be organized at the primary level of care
with special emphasis on increasing the awareness for
diabetes. A important health workforce that is not
used effectively, pharmacists, can also play a promin-
ent role in decreasing the awareness figures for
diabetes as well. There are more than 20 000 commu-
nity pharmacists in Turkey scattered in all geograph-
ical regions of the country with easy access. The
discussion to redefine the role of these pharmacists
has already started in Turkey and the pharmacists are
eager to widen their roles as dispensers of pharma-
ceuticals. This well educated and already available
workforce can be used to increase the awareness
levels of diabetes in the community without extra ef-
fort and cost.
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